Clinical Trial Update: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) [Phase 2]

View source ↗

Summary

Phase 2 safety trial evaluating lisocabtagene maraleucel (JCAR017) for relapsed/refractory B-cell non-Hodgkin lymphoma in the outpatient setting has completed, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Lisocabtagene maraleucel (lisocabtagene maraleucel)

Snippet

Sponsor: Juno Therapeutics, a Subsidiary of Celgene | Conditions: Lymphoma, Non-Hodgkin, Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-12-06